You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Drugs in ATC Class D10


✉ Email this page to a colleague

« Back to Dashboard


Subclasses in ATC: D10 - ANTI-ACNE PREPARATIONS

Market Dynamics and Patent Landscape for ATC Class D10: Anti-Acne Preparations

Last updated: February 20, 2026

What Is the Current Market Size and Growth Trajectory for Anti-Acne Preparations?

The global market for anti-acne preparations, classified under ATC D10, was valued at approximately $10 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2028. Factors driving growth include increased awareness, rising prevalence of acne among adolescents and adults, and expanding availability of new formulations.

Market Segments

Segment Type Market Share (2022) Description
Topical Formulations 70% Creams, gels, lotions targeting surface bacteria
Oral Medications 25% Antibiotics, isotretinoin, hormonal therapies
Devices and Aesthetic Procedures 5% Light therapy, chemical peels

Regional Distribution

Region Market Share (2022) Growth Drivers
North America 40% High prevalence, advanced healthcare infrastructure
Europe 25% Increased consumer awareness, growing skincare market
Asia-Pacific 25% Rising acne incidence, expanding dermatology sector
Rest of the World 10% Variable healthcare access, emerging markets

How Does Patent Activity Shape Innovation and Competition?

The patent landscape for ATC D10 focuses mainly on new formulation methods, combination therapies, and delivery systems. The number of active patents has increased steadily over the past decade, indicating ongoing innovation.

Patent Trends (2013-2022)

  • Total patents filed: 820
  • Patents granted: 670
  • Annual filings peaked at 110 filings in 2018
  • Patent expiration predominantly occurs between 2028-2033

Key Patent Holders

Company Number of Patents Focus Areas
Johnson & Johnson 130 Topical retinoids, combination agents
Galderma 110 Benzoyl peroxide patents, nanotechnology delivery systems
Teva Pharmaceuticals 90 Generic formulations, novel delivery methods
Novartis 70 Isotretinoin formulations, hormonal agents

Patent Filing Strategies

  • Use of patent families to extend market exclusivity
  • Filing in multiple jurisdictions to prevent patent circumvention
  • Combination claims to cover multi-component formulations

What Are the Key Innovation Areas?

  • Novel delivery systems such as nanosystems and sustained-release formulations
  • Combination therapies targeting multiple pathogenic pathways
  • Formulations with reduced side effects and improved tolerability
  • Use of bio-adhesive and bioavailability-enhancing technologies

How Is Competitive Landscape Evolving?

Emerging companies are focusing on over-the-counter products with natural ingredients. Larger pharmaceutical firms are investing in patented prescription therapies, especially oral isotretinoin and hormonal agents.

Competitive Strategies

  • Strategic patent filings to protect new formulations
  • Mergers and acquisitions to expand patent portfolios
  • Investment in R&D to develop next-generation products

What Regulatory and Legal Factors Influence Market and Patent Strategies?

  • Patent term extensions are possible in some jurisdictions, extending exclusivity beyond 20 years
  • Regulatory approvals impose stringent requirements for safety and efficacy
  • Patent challenges and litigation are common around blockbuster formulations
  • Variations exist across regions, impacting patent filing and enforcement strategies

Key Takeaways

  • The anti-acne market is poised for steady growth driven by new formulations and expanded access.
  • Patent activity is robust, with a focus on innovative delivery systems and combination therapies.
  • Key patent holders invest heavily in R&D, using strategic filings to extend patent life.
  • Emerging players emphasize natural products, while established companies focus on advanced, patented formulations.
  • Regulatory conditions influence patent strategy and market entry timing significantly.

Frequently Asked Questions

1. How long do patents typically last in the anti-acne market?

Patents are granted for 20 years from the filing date, with potential extensions in some jurisdictions, usually through patent term extensions or supplementary protection certificates.

2. Which companies lead in patent filings for D10 anti-acne preparations?

Johnson & Johnson, Galderma, and Teva Pharmaceuticals are the top patent filers, each focusing on different aspects such as formulations, delivery systems, and combination therapies.

3. What are the primary areas of innovation in anti-acne patents?

Formulation delivery systems like nanosystems, combination therapies, and reduced side-effect formulations are primary innovation areas.

4. How does the regional patent landscape impact market access?

Differences in patent laws and enforcement affect market exclusivity; companies often file in multiple jurisdictions to maximize protection.

5. What are upcoming trends in anti-acne patent filings?

Growth in patents related to bio-adhesive formulations, natural ingredients, and advanced delivery mechanisms is evident, with increased activity in Asia-Pacific markets.


References

[1] MarketWatch. (2023). Global Anti-Acne Market Report.
[2] World Intellectual Property Organization. (2022). Patent Filing Trends.
[3] Statista. (2023). Market Share in the Anti-Acne Skin Care Sector.
[4] European Patent Office. (2022). Patent Statistics for Dermatology.
[5] U.S. Patent and Trademark Office. (2022). Patent Landscape for Acne Medications.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.